Supernus Pharma Cash Flow - Annual (NASDAQ:SUPN)

Add to My Stocks
$44.7 $1.52 (3.52%) SUPN stock closing price Mar 16, 2018 (Closing)

The Supernus Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Supernus Pharma profits and Supernus Pharma debt. This statement can tell if a company is running out of money while still being profitable and is useful in Supernus Pharma stock analysis. Supernus Pharma had a positive net income cash flow of $91.22M for the latest 2016. This report is very useful in measuring the short term viability of a company. SUPN decrease in investments stood at a value of $-35.96M for the latest year 2016.

View details of Supernus Pharma cash flows for latest & last 10 financial years
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2016201520142013201220112010
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow2.91M1.66M3.01M3.77M1.2M1.09M1.18M
Net Increase (Decrease) in Assets Liabilities8.44M10.06M-17.5M5.67M-3.21M-5.85M
Cash From (used in) Discontinued Operations------75.01M-0.96M
Other Adjustments Net-35.77M6.37M2.34M24.87M1.09M-16.26M-0.15M
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-1.6M-2.1M-0.59M-1.64M-0.75M-0.68M-0.29M
Acquisition Disposition of Subsidiaires-------
Increase (Decrease) in Investments-15.54M-25.62M--9.76M-48.2M8.98M26.11M
Other Cash Inflow (Outflow) from Investment Activities-18.82M-8.5M-4.5M-0.7M-25.6M-
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares2.05M1.86M-2.43M100.73M--
Issuance (Repayment) of Debt Securities---65.65M-6.77M30M-
Increase (Decrease) in Bank & Other Borrowings-------
Payment of Dividends & Other Cash Distributions-------
Other Cash from (used by) Financing Activities----5.35M-6.04M-2.94M-0.94M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year33.49M36.39M32.98M40.3M48.54M23.74M31.4M
Cash & Equivalents at Year End66.39M34.15M36.39M32.98M40.3M48.54M23.74M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Supernus Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Supernus Pharma stock price history.
The statement of cash flows can be categorized into three main sections:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Supernus Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Supernus Pharma stock price movement.
  • The cash generated from the core business or operations was a positive at $66.81M for Supernus Pharma in the latest 2016. For an internet company, this would include all those activities which are involved in eventually selling advertisement space on its website or any online service.
  • Cash Flow from investment activities: Supernus Pharma used $-35.96M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Supernus Pharma earned $2.05M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Supernus Pharma Cash Flow

FCF margin

Annual Cash Flow Statements For Supernus Pharmaceuticals Inc Peers

Akorn cash flow, Catalent cash flow, Impax Lab cash flow, Dr. Reddy's Laboratories cash flow, Relypsa cash flow